[go: up one dir, main page]

SK15002003A3 - Použitie 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)etyl]- 1,2,3,6-tetrahydropyridín-4-yl]-6-chlór-1H-indolu - Google Patents

Použitie 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)etyl]- 1,2,3,6-tetrahydropyridín-4-yl]-6-chlór-1H-indolu Download PDF

Info

Publication number
SK15002003A3
SK15002003A3 SK1500-2003A SK15002003A SK15002003A3 SK 15002003 A3 SK15002003 A3 SK 15002003A3 SK 15002003 A SK15002003 A SK 15002003A SK 15002003 A3 SK15002003 A3 SK 15002003A3
Authority
SK
Slovakia
Prior art keywords
indol
dihydro
acetyl
chloro
ethyl
Prior art date
Application number
SK1500-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Klaus Peter Hertel
Jorn Arny
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of SK15002003A3 publication Critical patent/SK15002003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Recrystallisation Techniques (AREA)
SK1500-2003A 2001-05-09 2002-05-07 Použitie 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)etyl]- 1,2,3,6-tetrahydropyridín-4-yl]-6-chlór-1H-indolu SK15002003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100732 2001-05-09
PCT/DK2002/000298 WO2002089797A1 (en) 2001-05-09 2002-05-07 Treatment of adhd

Publications (1)

Publication Number Publication Date
SK15002003A3 true SK15002003A3 (sk) 2004-05-04

Family

ID=8160484

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1500-2003A SK15002003A3 (sk) 2001-05-09 2002-05-07 Použitie 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)etyl]- 1,2,3,6-tetrahydropyridín-4-yl]-6-chlór-1H-indolu

Country Status (23)

Country Link
US (1) US7294638B2 (is)
EP (1) EP1387682A1 (is)
JP (1) JP2004528361A (is)
KR (1) KR20040007544A (is)
CN (1) CN1507351A (is)
AR (1) AR033287A1 (is)
BG (1) BG108400A (is)
BR (1) BR0209443A (is)
CA (1) CA2446652A1 (is)
CO (1) CO5540378A2 (is)
CZ (1) CZ20033197A3 (is)
EA (1) EA200301221A1 (is)
HR (1) HRP20030852A2 (is)
HU (1) HUP0400075A2 (is)
IL (1) IL158413A0 (is)
IS (1) IS6992A (is)
MX (1) MXPA03010136A (is)
NO (1) NO20034972L (is)
NZ (1) NZ528896A (is)
PL (1) PL367778A1 (is)
SK (1) SK15002003A3 (is)
WO (1) WO2002089797A1 (is)
ZA (1) ZA200307955B (is)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003236207A1 (en) * 2002-05-31 2003-12-19 H. Lundbeck A/S The hydrochloride of (s)-(+)-3-(1-(2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)-6-chloro-1h-indole
EP1812390A2 (en) * 2004-10-22 2007-08-01 Mark Froimowitz Methylphenidate analogs and methods of use thereof
WO2009136410A2 (en) 2008-04-19 2009-11-12 Nisarga Biotech Pvt. Ltd. Herbal composition for reducing add/adhd and method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
ZA9711376B (en) 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
WO2002046156A2 (en) * 2000-12-06 2002-06-13 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands

Also Published As

Publication number Publication date
CO5540378A2 (es) 2005-07-29
KR20040007544A (ko) 2004-01-24
MXPA03010136A (es) 2004-03-10
EP1387682A1 (en) 2004-02-11
WO2002089797A8 (en) 2004-03-25
US20040152737A1 (en) 2004-08-05
ZA200307955B (en) 2004-10-13
HUP0400075A2 (hu) 2004-04-28
BR0209443A (pt) 2004-08-03
WO2002089797A1 (en) 2002-11-14
CN1507351A (zh) 2004-06-23
NZ528896A (en) 2004-12-24
US7294638B2 (en) 2007-11-13
NO20034972D0 (no) 2003-11-07
HRP20030852A2 (en) 2005-06-30
PL367778A1 (en) 2005-03-07
CA2446652A1 (en) 2002-11-14
JP2004528361A (ja) 2004-09-16
IL158413A0 (en) 2004-05-12
EA200301221A1 (ru) 2004-04-29
NO20034972L (no) 2003-11-07
AR033287A1 (es) 2003-12-10
CZ20033197A3 (en) 2004-06-16
BG108400A (bg) 2004-11-30
IS6992A (is) 2003-10-13

Similar Documents

Publication Publication Date Title
RU2165760C2 (ru) Применение антагонистов серотонина (5нт3) для лечения фибромиалгии
DeBattista et al. Antidepressant agents
Papp et al. The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats
JP5922515B2 (ja) 線維筋痛症候群の長期治療のためのミルナシプラン
LÉAN et al. Beneficial effects of serotonin precursors in postanoxic action myoclonus
JPH02290872A (ja) ５―クロロ―１―（４―フルオロフェニル）　―３―（１―（２―　（２―イミダゾリジノン―１―イル）エチル）　―４―ピペリジル）―１ｈ―インドールまたはその薬学的に容認できる酸付加塩を使用する方法
CN1308538A (zh) 对过度增殖疾病的治疗
Saletu-Zyhlarz et al. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients
AU2004248890A1 (en) Gaboxadol for treating depression and other affective disorders
Fischhof et al. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID)
Tortella et al. Suppressant effects of selective 5-HT2 antagonists on rapid eye movement sleep in rats
SK15002003A3 (sk) Použitie 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)etyl]- 1,2,3,6-tetrahydropyridín-4-yl]-6-chlór-1H-indolu
US10709687B2 (en) FLT3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US6849654B2 (en) 5-methoxy-carbonylamino-N-acetyltryptamine compounds and derivates thereof
Mori et al. Effects of dopamine-and serotonin-related compounds on methamphetamine-induced self-injurious behavior in mice
US6239162B1 (en) Method for treating depression
JP2017061506A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
Gavras et al. Safety and tolerability of eprosartan
US20030092735A1 (en) Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome
CN1447809A (zh) 神经变性疾病的预防和治疗药物
HK1067041A (en) Treatment of adhd
AU2002254875A1 (en) Treatment of ADHD
HUP9904578A2 (hu) Xanomelin alkalmazása bipoláris depresszió kezelésére szolgáló gyógyszerkészítmények előállítására
Van Riezen et al. Effects of various drugs supposed to interact with serotonin on PGO frequency changes induced by reserpine and 5-hydroxytryptophan.
EP1942891A1 (en) Novel combination of drugs as antidepressant

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure